{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:16:46Z","timestamp":1789514206152,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T00:00:00Z","timestamp":1495238400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s10067-017-3672-z","type":"journal-article","created":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T14:37:50Z","timestamp":1495291070000},"page":"1459-1469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["IL-6 blockade in the management of non-infectious uveitis"],"prefix":"10.1007","volume":"36","author":[{"given":"Giuseppe","family":"Lopalco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orso Maria","family":"Lucherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,20]]},"reference":[{"key":"3672_CR1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","volume":"80","author":"A Rothova","year":"1996","unstructured":"Rothova A, Suttorp-van Schulten MS, Frits Treffers W et al (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80:332\u2013336","journal-title":"Br J Ophthalmol"},{"key":"3672_CR2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.pop.2015.05.003","volume":"42","author":"JP Dunn","year":"2015","unstructured":"Dunn JP (2015) Uveitis. Prim Care 42:305\u2013323","journal-title":"Prim Care"},{"key":"3672_CR3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jbspin.2015.06.002","volume":"82","author":"P S\u00e8ve","year":"2015","unstructured":"S\u00e8ve P, Kodjikian L, Ad\u00e9la\u00efde L et al (2015) Uveitis in adults: what do rheumatologists need to know? Joint Bone Spine 82:308\u2013314","journal-title":"Joint Bone Spine"},{"key":"3672_CR4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12016-014-8436-9","volume":"49","author":"I Foeldvari","year":"2015","unstructured":"Foeldvari I (2015) Ocular involvement in juvenile idiopathic arthritis: classification and treatment. Clin Rev Allergy Immunol 49:271\u2013277","journal-title":"Clin Rev Allergy Immunol"},{"key":"3672_CR5","first-page":"653539","volume":"2014","author":"UC Park","year":"2014","unstructured":"Park UC, Kim TW, Yu HG (2014) Immunopathogenesis of ocular Beh\u00e7et\u2019s disease. J Immunol Res 2014:653539","journal-title":"J Immunol Res"},{"key":"3672_CR6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/jfb6030650","volume":"6","author":"DJ Lee","year":"2015","unstructured":"Lee DJ (2015) Intraocular implants for the treatment of autoimmune uveitis. J Funct Biomater 6:650\u2013666","journal-title":"J Funct Biomater"},{"key":"3672_CR7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00296-015-3231-3","volume":"35","author":"R Bou","year":"2015","unstructured":"Bou R, Ad\u00e1n A, Borr\u00e1s F et al (2015) Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int 35:777\u2013785","journal-title":"Rheumatol Int"},{"key":"3672_CR8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.survophthal.2011.05.003","volume":"56","author":"K Durrani","year":"2011","unstructured":"Durrani K, Zakka FR, Ahmed M et al (2011) Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol 56:474\u2013510","journal-title":"Surv Ophthalmol"},{"key":"3672_CR9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/09273948.2011.633205","volume":"20","author":"JN Martel","year":"2012","unstructured":"Martel JN, Esterberg E, Nagpal A et al (2012) Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm 20:18\u201326","journal-title":"Ocul Immunol Inflamm"},{"key":"3672_CR10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375:932\u2013943","journal-title":"N Engl J Med"},{"key":"3672_CR11","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388:1183\u20131192","journal-title":"Lancet"},{"key":"3672_CR12","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum 52:2478\u20132484","journal-title":"Arthritis Rheum"},{"key":"3672_CR13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler EB, Smith JR, Wertheim MS et al (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123:903\u2013912","journal-title":"Arch Ophthalmol"},{"key":"3672_CR14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW et al (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121:785\u2013796","journal-title":"Ophthalmology"},{"key":"3672_CR15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/14740338.2015.972363","volume":"14","author":"M Cordero-Coma","year":"2015","unstructured":"Cordero-Coma M, Salazar-M\u00e9ndez R, Garzo-Garc\u00eda I et al (2015) Drug-induced uveitis. Expert Opin Drug Saf 14:111\u2013126","journal-title":"Expert Opin Drug Saf"},{"key":"3672_CR16","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","volume":"56","author":"LL Lim","year":"2007","unstructured":"Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56:3248\u20133252","journal-title":"Arthritis Rheum"},{"key":"3672_CR17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/rheumatology\/kep046","volume":"48","author":"CI Da\u00efen","year":"2009","unstructured":"Da\u00efen CI, Monnier A, Claudepierre P et al (2009) Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 48:883\u2013886","journal-title":"Rheumatology (Oxford)"},{"key":"3672_CR18","first-page":"645","volume":"21","author":"PJ Hashkes","year":"2003","unstructured":"Hashkes PJ, Shajrawi I (2003) Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 21:645\u2013646","journal-title":"Clin Exp Rheumatol"},{"key":"3672_CR19","doi-asserted-by":"crossref","unstructured":"Fabiani C, Sota J, Tosi GM, et al (2016) The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. Clin Rheumatol [Epub ahead of print].","DOI":"10.1007\/s10067-016-3527-z"},{"key":"3672_CR20","first-page":"1","volume":"5","author":"CM Deuter","year":"2016","unstructured":"Deuter CM, Zierhut M, Igney-Oertel A et al (2016) Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm 5:1\u20136","journal-title":"Ocul Immunol Inflamm"},{"key":"3672_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273948.2016.1231331","volume":"11","author":"V Calvo-R\u00edo","year":"2016","unstructured":"Calvo-R\u00edo V, Blanco R, Santos-G\u00f3mez M et al (2016) Efficacy of anti-IL6-receptor tocilizumab in refractory cystoid macular edema of birdshot retinochoroidopathy\u2014report of two cases and literature review. Ocul Immunol Inflamm 11:1\u20136","journal-title":"Ocul Immunol Inflamm"},{"key":"3672_CR22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09273948.2011.606593","volume":"19","author":"A Muselier","year":"2011","unstructured":"Muselier A, Bielefeld P, Bidot S et al (2011) Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 19:382\u2013383","journal-title":"Ocul Immunol Inflamm"},{"key":"3672_CR23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","volume":"45","author":"A Deroux","year":"2016","unstructured":"Deroux A, Chiquet C, Bouillet L (2016) Tocilizumab in severe and refractory Behcet\u2019s disease: four cases and literature review. Semin Arthritis Rheum 45:733\u2013737","journal-title":"Semin Arthritis Rheum"},{"issue":"4 Suppl 84","key":"3672_CR24","first-page":"S54","volume":"32","author":"V Calvo-R\u00edo","year":"2014","unstructured":"Calvo-R\u00edo V, de la Hera D, Beltr\u00e1n-Catal\u00e1n E et al (2014) Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol 32(4 Suppl 84):S54\u2013S57","journal-title":"Clin Exp Rheumatol"},{"issue":"4 Suppl 84","key":"3672_CR25","first-page":"S75","volume":"32","author":"M Papo","year":"2014","unstructured":"Papo M, Bielefeld P, Vallet H et al (2014) Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol 32(4 Suppl 84):S75\u2013S79","journal-title":"Clin Exp Rheumatol"},{"key":"3672_CR26","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s00417-012-2243-x","volume":"251","author":"A Ad\u00e1n","year":"2013","unstructured":"Ad\u00e1n A, Lloren\u00e7 V, Mesquida M et al (2013) Tocilizumab treatment for recalcitrant uveitic macular edema. Graefes Arch Clin Exp Ophthalmol 251:2249\u20132250","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3672_CR27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987\u2013997","journal-title":"Lancet"},{"key":"3672_CR28","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M et al (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371:998\u20131006","journal-title":"Lancet"},{"key":"3672_CR29","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","volume":"106","author":"N Nishimoto","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627\u20132632","journal-title":"Blood"},{"key":"3672_CR30","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cytogfr.2015.07.004","volume":"26","author":"F Schaper","year":"2015","unstructured":"Schaper F, Rose-John S (2015) Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev 26:475\u2013487","journal-title":"Cytokine Growth Factor Rev"},{"key":"3672_CR31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.smim.2013.12.004","volume":"26","author":"JJ Babon","year":"2014","unstructured":"Babon JJ, Varghese LN, Nicola NA (2014) Inhibition of IL-6 family cytokines by SOCS3. Semin Immunol 26:13\u201319","journal-title":"Semin Immunol"},{"key":"3672_CR32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejcb.2010.10.007","volume":"90","author":"A Chalaris","year":"2011","unstructured":"Chalaris A, Garbers C, Rabe B et al (2011) The soluble interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 90:484\u2013494","journal-title":"Eur J Cell Biol"},{"key":"3672_CR33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","volume":"268","author":"T Jostock","year":"2001","unstructured":"Jostock T, M\u00fcllberg J, Ozbek S et al (2001) Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor trans-signaling responses. Eur J Biochem 268:160\u2013167","journal-title":"Eur J Biochem"},{"key":"3672_CR34","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6:a016295","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3672_CR35","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T (2010) IL-6: regulator of Treg\/Th17 balance. Eur J Immunol 40:1830\u20131835","journal-title":"Eur J Immunol"},{"key":"3672_CR36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/092739490500282","volume":"12","author":"VL Perez","year":"2004","unstructured":"Perez VL, Papaliodis GN, Chu D et al (2004) Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm 12:193\u2013201","journal-title":"Ocul Immunol Inflamm"},{"key":"3672_CR37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/ken489","volume":"48","author":"T Yoshimura","year":"2009","unstructured":"Yoshimura T, Sonoda KH, Ohguro N et al (2009) Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 48:347\u2013354","journal-title":"Rheumatology (Oxford)"},{"key":"3672_CR38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ajo.2011.01.031","volume":"152","author":"JJ Kuiper","year":"2011","unstructured":"Kuiper JJ, Mutis T, de Jager W et al (2011) Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy. Am J Ophthalmol 152:177\u2013182","journal-title":"Am J Ophthalmol"},{"key":"3672_CR39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","volume":"139","author":"AM El-Asrar","year":"2011","unstructured":"El-Asrar AM, Struyf S, Kangave D et al (2011) Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol 139:177\u2013184","journal-title":"Clin Immunol"},{"key":"3672_CR40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2174\/1566524015666150731100012","volume":"15","author":"W Chen","year":"2015","unstructured":"Chen W, Zhao B, Jiang R et al (2015) Cytokine expression profile in aqueous humor and sera of patients with acute anterior uveitis. Curr Mol Med 15:543\u2013549","journal-title":"Curr Mol Med"},{"key":"3672_CR41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.exer.2010.04.009","volume":"91","author":"S Hohki","year":"2010","unstructured":"Hohki S, Ohguro N, Haruta H et al (2010) Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res 91:162\u2013170","journal-title":"Exp Eye Res"},{"key":"3672_CR42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10753-015-0229-7","volume":"39","author":"L Zhang","year":"2016","unstructured":"Zhang L, Wan F, Song J, Tang K et al (2016) Imbalance between Th17 cells and regulatory T cells during monophasic experimental autoimmune uveitis. Inflammation 39:113\u2013122","journal-title":"Inflammation"},{"key":"3672_CR43","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1167\/iovs.16-19758","volume":"57","author":"AM Abu El-Asrar","year":"2016","unstructured":"Abu El-Asrar AM, Berghmans N, Al-Obeidan SA et al (2016) The cytokine interleukin-6 and the chemokines CCL20 and CXCL13 are novel biomarkers of specific endogenous uveitic entities. Invest Ophthalmol Vis Sci 57:4606\u20134613","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3672_CR44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.biocel.2016.08.003","volume":"79","author":"NA Sims","year":"2016","unstructured":"Sims NA (2016) Cell-specific paracrine actions of IL-6 family cytokines from bone, marrow and muscle that control bone formation and resorption. Int J Biochem Cell Biol 79:14\u201323","journal-title":"Int J Biochem Cell Biol"},{"key":"3672_CR45","doi-asserted-by":"crossref","first-page":"36012","DOI":"10.1074\/jbc.M112.390625","volume":"287","author":"YC-RR Wang R-XX","year":"2012","unstructured":"Wang R-XX YC-RR, Mahdi RM et al (2012) Novel IL27p28\/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1\/Th17 cells and promoting expansion of regulatory T cells. J Biol Chem 287:36012\u201336021","journal-title":"J Biol Chem"},{"key":"3672_CR46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14728222.2012.660307","volume":"16","author":"GH Waetzig","year":"2012","unstructured":"Waetzig GH, Rose-John S (2012) Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets 16:225\u2013236","journal-title":"Expert Opin Ther Targets"},{"key":"3672_CR47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/rheumatology\/kem053","volume":"46","author":"A Heiligenhaus","year":"2007","unstructured":"Heiligenhaus A, Niewerth M, Ganser G et al (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46:1015\u20131019","journal-title":"Rheumatology (Oxford)"},{"key":"3672_CR48","first-page":"92","volume":"112","author":"A Heiligenhaus","year":"2015","unstructured":"Heiligenhaus A, Minden K, F\u00f6ll D et al (2015) Uveitis in juvenile idiopathic arthritis. Dtsch Arztebl Int 112:92\u2013100","journal-title":"Dtsch Arztebl Int"},{"key":"3672_CR49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3928\/0191-3913-19980101-13","volume":"35","author":"MI Boone","year":"1998","unstructured":"Boone MI, Moore TL, Cruz OA (1998) Screening for uveitis in juvenile rheumatoid arthritis. J Pediatr Ophthalmol Strabismus 35:41\u201343","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"3672_CR50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3345\/kjp.2010.53.11.931","volume":"53","author":"KH Kim","year":"2010","unstructured":"Kim KH, Kim DS (2010) Juvenile idiopathic arthritis: diagnosis and differential diagnosis. Korean J Pediatr 53:931\u2013935","journal-title":"Korean J Pediatr"},{"key":"3672_CR51","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11926-014-0454-3","volume":"16","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Wallace C (2014) Judicious use of biologicals in juvenile idiopathic arthritis. Curr Rheumatol Rep 16:454","journal-title":"Curr Rheumatol Rep"},{"key":"3672_CR52","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","volume":"18","author":"G Horneff","year":"2016","unstructured":"Horneff G, Klein A, Klotsche J et al (2016) Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther 18:272","journal-title":"Arthritis Res Ther"},{"key":"3672_CR53","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3899\/jrheum.160231","volume":"43","author":"C Tappeiner","year":"2016","unstructured":"Tappeiner C, Mesquida M, Ad\u00e1n A et al (2016) Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 43:2183\u20132188","journal-title":"J Rheumatol"},{"key":"3672_CR54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/09273948.2013.866254","volume":"22","author":"AC Tsang","year":"2014","unstructured":"Tsang AC, Roth J, Gottlieb C (2014) Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm 22:155\u2013157","journal-title":"Ocul Immunol Inflamm"},{"key":"3672_CR55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00417-013-2466-5","volume":"252","author":"A Ad\u00e1n","year":"2014","unstructured":"Ad\u00e1n A, Mesquida M, Lloren\u00e7 V et al (2014) Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. Graefes Arch Clin Exp Ophthalmol 252:163\u2013164","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3672_CR56","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","volume":"39","author":"C Tappeiner","year":"2012","unstructured":"Tappeiner C, Heinz C, Ganser G et al (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39:1294\u20131295","journal-title":"J Rheumatol"},{"key":"3672_CR57","doi-asserted-by":"crossref","unstructured":"Calvo-R\u00edo V, Santos-G\u00f3mez M, Calvo I, et al (2016) Anti-IL6-R tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-TNF therapy\u2014a multicenter study of 25 patients. Arthritis Rheumatol [Epub ahead of print].","DOI":"10.1002\/art.39940"},{"key":"3672_CR58","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1111\/aos.13015","volume":"94","author":"S Silpa-Archa","year":"2016","unstructured":"Silpa-Archa S, Oray M, Preble JM et al (2016) Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol 94:e400\u2013e406","journal-title":"Acta Ophthalmol"},{"key":"3672_CR59","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","volume":"251","author":"A Ad\u00e1n","year":"2013","unstructured":"Ad\u00e1n A, Mesquida M, Lloren\u00e7 V et al (2013) Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 251:2627\u20132632","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3672_CR60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/09273940903311999","volume":"18","author":"MP Paroli","year":"2010","unstructured":"Paroli MP, Spinucci G, Fabiani C et al (2010) Retinal complications of juvenile idiopathic arthritis-related uveitis: a microperimetry and optical coherence tomography study. Ocul Immunol Inflamm 18:54\u201359","journal-title":"Ocul Immunol Inflamm"},{"key":"3672_CR61","first-page":"1","volume":"14","author":"D Rigante","year":"2010","unstructured":"Rigante D (2010) The protean visage of systemic autoinflammatory syndromes: a challenge for inter-professional collaboration. Eur Rev Med Pharmacol Sci 14:1\u201318","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6 Suppl 94","key":"3672_CR62","first-page":"S3","volume":"33","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Seyahi E, Fresko I et al (2015) Beh\u00e7et\u2019s syndrome: a critical digest of the 2014-2015 literature. Clin Exp Rheumatol 33(6 Suppl 94):S3\u201314","journal-title":"Clin Exp Rheumatol"},{"key":"3672_CR63","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N et al (2003) The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60\u201376","journal-title":"Medicine (Baltimore)"},{"key":"3672_CR64","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G et al (2017) Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:183\u2013189","journal-title":"Clin Rheumatol"},{"key":"3672_CR65","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G et al (2017) Adalimumab effectiveness in Beh\u00e7et\u2019s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36:451\u2013455","journal-title":"Clin Rheumatol"},{"key":"3672_CR66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F et al (2014) Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et\u2019s disease: a case series. Dermatology 228:211\u2013214","journal-title":"Dermatology"},{"key":"3672_CR67","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fphar.2016.00380","volume":"7","author":"A Vitale","year":"2016","unstructured":"Vitale A, Insalaco A, Sfriso P et al (2016) A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol 7:380","journal-title":"Front Pharmacol"},{"key":"3672_CR68","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G et al (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:191\u2013197","journal-title":"Clin Rheumatol"},{"key":"3672_CR69","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","volume":"22","author":"T Hirano","year":"2012","unstructured":"Hirano T, Ohguro N, Hohki S et al (2012) A case of Beh\u00e7et\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 22:298\u2013302","journal-title":"Mod Rheumatol"},{"key":"3672_CR70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","volume":"114","author":"LS Shapiro","year":"2012","unstructured":"Shapiro LS, Farrell J, Borhani Haghighi A (2012) Tocilizumab treatment for neuro-Behcet\u2019s disease, the first report. Clin Neurol Neurosurg 114:297\u2013298","journal-title":"Clin Neurol Neurosurg"},{"key":"3672_CR71","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12026-013-8411-1","volume":"56","author":"F Caso","year":"2013","unstructured":"Caso F, Iaccarino L, Bettio S et al (2013) Refractory pemphigus foliaceus and Beh\u00e7et\u2019s disease successfully treated with tocilizumab. Immunol Res 56:390\u2013397","journal-title":"Immunol Res"},{"key":"3672_CR72","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/rheumatology\/kev255","volume":"54","author":"W Terreaux","year":"2015","unstructured":"Terreaux W, Mestrallet S, Fauconier M et al (2015) Failure of tocilizumab therapy in a patient with mouth and genital ulcers with inflamed cartilage syndrome complicated by aortic aneurysm. Rheumatology (Oxford) 54:2111\u20132113","journal-title":"Rheumatology (Oxford)"},{"key":"3672_CR73","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.semarthrit.2016.03.006","volume":"46","author":"G Emmi","year":"2016","unstructured":"Emmi G, Silvestri E, Squatrito D et al (2016) Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Beh\u00e7et\u2019s disease. Semin Arthritis Rheum 46:e1\u2013e2","journal-title":"Semin Arthritis Rheum"},{"key":"3672_CR74","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/rheumatology\/ket130","volume":"52","author":"AP Diamantopoulos","year":"2013","unstructured":"Diamantopoulos AP, Hatemi G (2013) Lack of efficacy of tocilizumab in mucocutaneous Behcet\u2019s syndrome: report of two cases. Rheumatology (Oxford) 52:1923\u20131924","journal-title":"Rheumatology (Oxford)"},{"key":"3672_CR75","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Vitale A et al (2015) Paradoxical mucocutaneous flare in a case of Beh\u00e7et\u2019s disease treated with tocilizumab. Clin Rheumatol 34:1141\u20131143","journal-title":"Clin Rheumatol"},{"key":"3672_CR76","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/OPTH.S54929","volume":"8","author":"T Sato","year":"2014","unstructured":"Sato T, Minakuchi S, Mochizuki M et al (2014) Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis. Clin Ophthalmol 8:187\u2013190","journal-title":"Clin Ophthalmol"},{"key":"3672_CR77","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959\u20133964","journal-title":"Blood"},{"key":"3672_CR78","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/s10165-012-0691-0","volume":"23","author":"M Shibuya","year":"2013","unstructured":"Shibuya M, Fujio K, Morita K et al (2013) Successful treatment with tocilizumab in a case of Cogan\u2019s syndrome complicated with aortitis. Mod Rheumatol 23:577\u2013581","journal-title":"Mod Rheumatol"},{"key":"3672_CR79","first-page":"968180","volume":"2012","author":"T Oshitari","year":"2012","unstructured":"Oshitari T, Kajita F, Tobe A et al (2012) Refractory uveitis in a patient with Castleman disease successfully treated with tocilizumab. Case Rep Ophthalmol Med 2012:968180","journal-title":"Case Rep Ophthalmol Med"},{"key":"3672_CR80","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","volume":"113","author":"CW Lardenoye","year":"2006","unstructured":"Lardenoye CW, van Kooij B, Rothova A (2006) Impact of macular edema on visual acuity in uveitis. Ophthalmology 113:1446\u20131449","journal-title":"Ophthalmology"},{"key":"3672_CR81","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/02713683.2011.614370","volume":"37","author":"H Noma","year":"2012","unstructured":"Noma H, Funatsu H, Mimura T (2012) Vascular endothelial growth factor and interleukin-6 are correlated with serous retinal detachment in central retinal vein occlusion. Curr Eye Res 37:62\u201367","journal-title":"Curr Eye Res"},{"key":"3672_CR82","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.11143","volume":"48","author":"H Nakahara","year":"2003","unstructured":"Nakahara H, Song J, Sugimoto M et al (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48:1521\u20131529","journal-title":"Arthritis Rheum"},{"key":"3672_CR83","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bcp.2012.11.021","volume":"85","author":"HE Tzeng","year":"2013","unstructured":"Tzeng HE, Tsai CH, Chang ZL et al (2013) Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma. Biochem Pharmacol 85:531\u2013540","journal-title":"Biochem Pharmacol"},{"key":"3672_CR84","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1076\/ocii.10.4.239.15589","volume":"10","author":"A Rothova","year":"2002","unstructured":"Rothova A (2002) Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 10:239\u2013246","journal-title":"Ocul Immunol Inflamm"},{"key":"3672_CR85","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.ophtha.2014.06.050","volume":"121","author":"M Mesquida","year":"2014","unstructured":"Mesquida M, Molins B, Lloren\u00e7 V et al (2014) Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology 121:2380\u20132386","journal-title":"Ophthalmology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3672-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3672-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3672-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T17:25:42Z","timestamp":1692811542000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3672-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,20]]},"references-count":85,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["3672"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3672-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,20]]}}}